2012-10-06 19:23:42 - Recently published research from Global Markets Direct, "Oxagen Limited - Product Pipeline Review - 2012", is now available at Fast Market Research

Global Market Direct's pharmaceuticals report, "Oxagen Limited - Product Pipeline Review - 2012" provides data on the Oxagen Limited's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Oxagen Limited's corporate website, SEC filings, investor presentations and featured press releases, both from Oxagen Limited and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

* Oxagen Limited - Brief Oxagen Limited overview including business description, key information and facts, and its locations and subsidiaries.
* Review of current pipeline of Oxagen Limited human therapeutic division.
* Overview of

pipeline therapeutics across various therapy areas.
* Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
* Product profiles for late stage and clinical stage products of Oxagen Limited with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
* Recent updates of the Oxagen Limited's pipeline in the last quarter.
* Key discontinued and dormant projects.
* Latest news and deals relating to the products.


Full Report Details at
- www.fastmr.com/prod/468576_oxagen_limited_product_pipeline_revie ..


Reasons to buy

* Evaluate Oxagen Limited's strategic position with total access to detailed information on its product pipeline.
* Assess the growth potential of Oxagen Limited in its therapy areas of focus.
* Identify new drug targets and therapeutic classes in the Oxagen Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
* Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
* Exploit collaboration and partnership opportunities with Oxagen Limited.
* Avoid Intellectual Property Rights related issues.
* Explore the dormant and discontinued projects of Oxagen Limited and identify potential opportunities in those areas.

Report Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Oxagen Limited Snapshot
Oxagen Limited Overview
Key Information
Key Facts
Oxagen Limited - Research and Development Overview
Key Therapeutic Areas
Oxagen Limited - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Oxagen Limited - Pipeline Products Glance
Oxagen Limited Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Oxagen Limited - Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Oxagen Limited - Drug Profiles
0C-2286
Product Description
Mechanism of Action
R&D Progress
OC-000459
Product Description
Mechanism of Action
R&D Progress
OC-002417
Product Description
Mechanism of Action
R&D Progress
OC-499
Product Description
Mechanism of Action
R&D Progress
ODC-9101
Product Description
Mechanism of Action
R&D Progress
Oxagen Limited - Pipeline Products by Route of Administration
Oxagen Limited - Pipeline Products By Mechanism of Action
Oxagen Limited - Dormant Projects
Oxagen Limited - Locations And Subsidiaries
Head Office
Oxagen Limited, Recent Developments
Oxagen Limited- Press Release
Dec 09, 2009: Oxagen Announces Completion Of Recruitment In Phase IIb Dose Range-Finding Clinical Trial In New Oral Treatment For Asthma
Nov 24, 2009: Oxagen Limited Raises Pound 16 Million In Series C Private Venture Capital Financing Led By Novartis Venture Funds
Financial Deals Landscape
Oxagen Limited, Deals Summary
Oxagen Limited, Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Oxagen Raises $27 Million In Series C Financing
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Oxagen Limited, Key Information
Oxagen Limited, Key Facts
Oxagen Limited - Pipeline by Indication, 2012
Oxagen Limited - Pipeline by Stage of Development, 2012
Oxagen Limited - Monotherapy Products in Pipeline, 2012
Oxagen Limited - Phase II, 2012
Oxagen Limited - Pre-Clinical, 2012
Oxagen Limited - Pipeline By Route of Administration, 2012
Oxagen Limited - Pipeline Products By Mechanism of Action, 2012
Oxagen Limited - Dormant Developmental Projects,2012
Oxagen Limited, Deals Summary
Oxagen Raises $27 Million In Series C Financing

List of Figures
Oxagen Limited - Pipeline by Indication, 2012
Oxagen Limited - Pipeline by Stage of Development, 2012
Oxagen Limited - Monotherapy Products in Pipeline, 2012
Oxagen Limited - Pipeline By Route of Administration, 2012
Oxagen Limited - Pipeline Products By Mechanism of Action, 2012

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.